NETHERLANDS REFERENCE LABORATORY FOR BACTERIAL MENINGITIS

BACTERIAL MENINGITIS IN THE NETHERLANDS

ANNUAL REPORT 2013

MC
Academic Medical Center
University of Amsterdam

RIVM
National Institute of Public Health and Environmental Protection

BACTERIAL MENINGITIS IN THE NETHERLANDS
ANNUAL REPORT 2013

NETHERLANDS REFERENCE LABORATORY FOR BACTERIAL MENINGITIS

Academic Medical Center (AMC)
and
National Institute of Public Health and the Environment (RIVM),
Department of Medical Microbiology, AMC
PO Box 22660 , 1100 DD Amsterdam
The Netherlands
Telephone
31 20 566 4874
31 20 566 4864
31 20 566 4861

E-mail: reflab@amc.uva.nl

Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM)
Bacterial meningitis in the Netherlands; annual report 2013
Amsterdam: University of Amsterdam, 2014

CONTENTS

1 INTRODUCTION

This is the **42th** Annual Report of the Netherlands Reference Laboratory for Bacterial Meningitis of the Academic Medical Center (AMC) and the National Institute of Public Health and the Environment (RIVM). The Reference Laboratory is located within the Department of Medical Microbiology of the AMC in Amsterdam. Nearly all clinical microbiology laboratories of the Netherlands collaborate by sending bacterial isolates and/or cerebrospinal fluid samples from patients with meningitis and we are most grateful to our colleagues for their cooperation.

The Reference Laboratory started collecting isolates of *Neisseria meningitidis* in 1959 and of other bacteria causing meningitis in 1975.

In the archives of the Reference Laboratory data from approximately 66,500 isolates are now available for studies on the epidemiology of bacterial meningitis and on the pathogenicity and antibiotic susceptibility of isolates.

The objectives of the Reference Laboratory are:
- to perform surveillance of bacterial meningitis;
- to describe the epidemiology of bacterial meningitis in the Netherlands;
- to provide keys for the development of potential vaccine components;
- to provide data about antibiotic susceptibility of isolates.

The information is presented in tables and figures and shortly discussed in the text.

We would appreciate receiving your opinion and suggestions on this report.

Amsterdam, October, 2014

dr. A. van der Ende PhD, biochemist
dr. L. Spanjaard MD PhD, medical microbiologist

2 ISOLATES, CSF SPECIMENS AND SERA RECEIVE

The Netherlands Reference Laboratory for Bacterial Meningitis collects isolates from cerebrospinal fluid (CSF) and blood from patients with proven meningitis (CSF and possibly blood culture positive) or with bacteraemia and suspected meningitis (blood culture positive only). Unless otherwise indicated, every isolate from CSF, from CSF and blood, and from blood represents a patient with meningitis, a patient with meningitis and bacteraemia, and a bacteraemia patient, respectively. Incidences have been calculated by dividing the number of isolates collected over one year (in a certain patient's age group) by the number of inhabitants over one year (in that age group) multiplied by 100,000. Population figures were obtained from Statistics Netherlands (Centraal Bureau voor de Statistiek, http://www.cbs.nl) using StatLine. By estimation, the Reference Laboratory receives about 90% of the isolates of Dutch meningitis patients, hence incidences presented in this report are likely to be underestimated.

In 2013, the Reference Laboratory received isolates from CSF and / or blood from 1416 patients, and 28 specimens of CSF and/or serum wich were positive in PCR (or crypt. agglutination.) (table 2.1/table 11.1). Of these patients, 292 were confirmed cases of bacterial meningitis.

Table 2.1

	Number of specimens
Isolate (CSF and/or blood)	1416
CSF samples (without isolate)	151
Sera (and other fluid, without isolate)	11
Total	1578

In 2013, 57 clinical microbiology laboratories submitted isolates to the Reference Laboratory.

Table 2.2 shows the 1416 isolates according to species and to laboratory where cases were diagnosed.

Table 2.2 Number of isolates from CSF and/or blood received in 2013, according to laboratory

Location	Laboratory	Nm	Hi	Sp	Ec	Sag	Lm	Spy	Sau	Cns	Cn	Ot	nv	Total
Alkmaar	MCA lab. Med. Microbiologie	4	5	10	-	1	1	1	2	-	-	1	-	25
Amersfoort	Meander Medisch Centrum	4	4	9	-	-	1	-	-	-	-	-	-	18
Amsterdam	Academisch Medisch Centrum AMC	3	5	2	-	-	1	1	-	-	-	-	-	4
	Academisch ziekenhuis VU	-	-	30	6	3	1	1	1	3	-	1	-	54
	Onze Lieve Vrouwe Gasthuis	1	4	7	2	6	1	1	2	-	-	1	-	25
	Slotervaart Ziekenhuis	-	-	9	-	-	-	-	-	-	-	-	-	9
Apeldoorn	Gelre Ziekenhuizen	2	5	13	-	1	-	-	1	1	-	1	-	24
Arnhem	Rijnstate	-	3	12	-	2	-	-	-	-	1	1	-	19
Breda	Amphia Ziekenhuis	1	6	8	3	4	3	2	-	1	2	-	-	30
Capelle ad IJssel	IJsselland Ziekenhuis	-	1	1	-	4	-	-	-	-	-	-	-	5
Delft	Reinier de Graaf groep	1	1	2	1	-	-	-	2	-	-	-	-	7
Den Bosch	Regionaal laboratorium Den Bosch	2	4	7	-	-	2	-	-	-	-	-	-	15
Den Haag	Medisch centrum Haaglanden	2	-	-	-	-	-	-	-	-	-	-	-	2
	Ziekenhuis Leijenburg	-	3	6	1	2	-	-	-	-	-	-	-	12
Deventer	Deventer Ziekenhuis	2	1	2	-	1	1	-	-	-	-	-	-	7
Doetinchem	Slingeland Ziekenhuis	2	3	3	1	3	-	-	-	-	-	-	-	12
Dordrecht	RLM Dordrecht / Gorinchem	6	1	63	-	4	-	-	-	-	-	1	-	75
Ede	Gelderse Vallei	3	2	3	-	1	1	-	-	1	-	1	-	12
Enschede	RLM Enschede	3	4	87	-	4	4	2	1	-	-	-	-	105
Etten Leur	Stichting Huisartsen laboratorium	-	-	1	-	-	-	-	-	-	-	-	-	1
Gouda	Groene Hart Ziekenhuis	-	-	4	-	-	-	-	-	-	-	-	-	4
Groningen	Certe, Lab. v. Infectieziekten	7	12	8	-	1	4	1	-	-	1	1	-	35
	UMCG	2	4	6	-	-	-	-	-	-	-	-	-	12
Haarlem	St. Streeklab voor de Volksgezondheid	4	9	96	1	3	1	4	-	-	1	1	-	120
Harderwijk	St. Jansdal Ziekenhuis	-	3	2	-	-	-	-	2	-	-	-	-	7
Heerlen	Atrium Medisch Centrum	2	2	41	-	1	1	-	-	-	-	-	-	47
Hengelo	LabMicTa	-	1	15	-	-	3	-	-	-	-	1	1	21
Hilversum	Centraal Bact. Ser. Lab.	1	-	5	-	-	1	1	-	-	-	1	-	9
Hoorn	Westfries gasthuis	-	2	4	-	-	1	1	1	-	-	-	-	9
Leeuwarden	Izore, centrum infectieziekten Friesland	2	5	100	-	5	2	-	-	-	-	-	-	114
Leiden	Diakonessen Ziekenhuis	3	1	6	-	-	-	2	-	-	-	-	-	12
	KML, Lab.voor Bacteriologie	1	3	10	2	-	1	-	-	-	1	1	-	19
Leiderdorp	Rijnland Ziekenhuis	1	-	3	-	-	-	-	-	-	-	-	-	4
Maastricht	Acad. Ziekenhuis Maastricht	-	1	3	-	-	-	-	-	-	-	-	-	4
Nieuwegein	St. Antonius Ziekenhuis	4	12	71	-	-	2	-	-	-	-	1	-	90
Nijmegen	Canisius Wilhelmina Ziekenhuis	2	3	3	-	1	3	-	-	-	-	1	-	13
	UMC St. Radboud	1	6	4	8	3	3	-	-	-	1	-	-	26
Roermond	St. Laurentius Ziekenhuis	-	-	3	-	-	1	-	-	-	-	-	-	4
Roosendaal	St. Fransiscus Ziekenhuis	2	2	4	1	1	-	-	-	-	-	1	-	11
Rotterdam	Erasmus MC Med. Microbiologie	2	2	2	-	-	-	2	7	-	-	-	-	15
Rotterdam	Ikazia Ziekenhuis	3	3	-	-	-	1	-	-	-	-	1	-	8
	Maasstad Ziekenhuis	4	2	3	-	-	1	-	-	-	-	-	-	10
	St.Franciscus Gasthuis	1	3	-	-	1	1	-	-	-	-	-	-	6
Schiedam	Vlietland locatie Schiedam	1	2	2	-	-	-	-	-	-	-	-	-	5
Sittard	Orbis Medisch Centrum	2	-	2	-	1	-	-	-	-	-	-	-	5
Terneuzen	ZorgSaam Zeeuws-Vlaanderen LVM	-	-	3	-	-	-	-	-	-	-	-	-	3

Location	Laboratory	Nm	Hi	Sp	Ec	Sag	Lm	Spy	Sau	Cns	Cn	Ot	nv	Total
Tilburg	Streeklab. Tilburg	1	7	66	-	4	-	1	-	-	-	1	-	80
Utrecht	Diakonessenhuis	2	3	4	-	6	1	1	-	-	-	1	-	18
	UMC Med. Microbiologie	3	-	11	-	-	2	-	-	-	-	-	-	16
Veldhoven	Lab. Med. Microbiologie	7	13	103	-	5	3	10	3	-	1	1	-	146
Velp	Ziekenhuis Velp	2	2	35	-	-	1	1	-	-	-	-	-	40
Venlo	Vie Curie medisch centrum	2	1	6	-	1	1	1	1	-	-	-	-	12
Vlissingen	Lab. Voor Med. Microbiologie & Imm.	1	-	-	-	-	-	1	-	-	-	-	-	1
Weert	St. Jans gasthuis	-	3	-	-	-	1	-	-	-	-	-	-	4
Woerden	Zuwe Hofpoort Ziekenhuis	-	1	1	-	-	-	-	-	-	-	-	-	2
Zaandam	Zaans Medisch Centrum	8	1	3	-	1	1	-	-	-	-	-	-	14
Zwolle	Isala Klinieken LMMI	4	-	2	-	2	-	-	-	-	-	1	-	9
Absolute total*		**111**	**160**	**906**	**26**	**72**	**52**	**31**	**23**	**6**	**8**	**20**	**1**	**1416**

Nm: *N. meningitidis*; **Hi:** *H. influenzae*; **Sp:** *S. pneumoniae*; **Ec:** *E. coli*; **Sag:** *S. agalactiae*; **Lm:** *L. monocytogenes*; **Spy:** *S.pyogenes*; **Sau:** *S. aureus*; **Cns:** Coagulase negative staphylococcus; **Cn:** *C. neoformans;* **ot:** other bacteria; **nv:** non-viable

The distribution of the isolates received in the 5 year period 2009 through 2013 is presented in table 2.3. The number of total isolates increased from 1304 in 2012 to 1416 in 2013. The number of cases of meningococcal disease was higher compared to the number of cases in 2012 (2013: 111; 2012: 81).Since June 2006, children born after the first of April 2006 are vaccinated with a conjugated polysaccharide vaccine against *Streptococcus pneumoniae*. The number of *S. pneumoniae* isolates from CSF decreased from more than 200 yearly before 2007 to 138 in 2012 and 2013. The number of *Listeria monocytogenes* was high in 2005 (81), most likely due to an intensified surveillance performed by the RIVM. In 2013, the number of *L. monocytogenes* isolates was similar to that in 2010 - 2012. The number of *Haemophilus influenzae* isolates increased, mainly due to a higher number of *H. influenzae* isolates from blood.

Table 2.3 Number of isolates from CSF and/or blood received in the years 2009 – 2013

Species	YEAR														
	2009			2010			2011			2012			2013		
	CSF	Blood	Total	CSF	Blood	Total	CSF	Blood	Total	CSF	Blood	Total	CSF	Blood	Total
N. meningitidis	52	87	139	53	79	132	37	53	90	41	40	81	39	72	111
H. influenzae	15	114	129	17	125	142	13	126	139	16	124	140	16	144	160
S. pneumoniae	190	735	925	176	658	834	163	753	916	138	731	869	138	768	906
E. coli	11	12	23	11	13	24	8	7	15	5	8	13	8	18	26
S. agalactiae	9	53	62	22	48	70	19	44	63	23	57	80	20	52	72
L. monocytogenes	13	44	57	16	42	58	8	53	61	9	50	59	6	46	52
S. pyogenes	6	5	11	6	7	13	4	10	14	3	9	12	9	22	31
S. aureus	10	-	10	8	-	8	4	-	4	7	1	8	5	18	23
Coag.neg.Staph.	6	-	6	6	-	6	-	-	-	6	-	6	6	-	6
C. neoformans	12	1	13	6	6	12	5	2	7	9	1	10	6	2	8
others	23	2	25	19	4	23	14	6	20	17	8	25	14	6	20
non viable	1	4	5	-	1	1	-	2	2	-	1	1	-	1	1
Total	348	1057	1405	340	983	1323	275	1056	1331	274	1030	1304	267	1149	1416

CSF: CSF or CSF and blood
blood: blood only

The incidence of isolation of the different bacterial species from CSF and/or blood over the years 2009 to 2013 is shown in table 2.4. The incidence of *N. meningitidis* infection was 37% higher than in 2012. This is due to a rise in the number of *N. meningitidis* group B cases. The incidence of *H. influenzae* infection was 54% lower than in the years before vaccination was introduced (2.1 in 1992; 0.95 in 2013). The incidence *of H. influenzae* infection increased from 2010 until now, mainly caused by an increase in the number of cases of bacteraemia due to unencapsulated *H. influenzae*.

Table 2.4 Number of isolates from CSF and/or blood per 100,000 inhabitants, 2009 - 2013

Species	YEAR				
	2009	2010	2011	2012	2013
N. meningitidis	0.84	0.80	0.54	0.48	0.66
H. influenzae	0.78	0.86	0.83	0.84	0.95
S. pneumoniae	5.61	5.03	5.50	5.19	5.40
E. coli	0.14	0.14	0.09	0.08	0.15
S. agalactiae	0.38	0.42	0.38	0.48	0.43
L. monocytogenes	0.35	0.35	0.37	0.35	0.31
S. pyogenes	0.07	0.08	0.08	0.07	0.18
S. aureus	0.06	0.05	0.02	0.05	0.14
Coag. neg. Staph.	0.04	0.04	-	0.04	0.04
C. neoformans	0.08	0.07	0.04	0.06	0.05
others	0.15	0.14	0.12	0.15	0.12
non viable	0.03	-	0.01	0.01	0.01
Total	8.52	7.98	7.99	7.79	8.44

Table 2.5 shows the distribution of isolates according to the specimen from which they were cultured. The predominant species were *N. meningitidis, H. influenzae* and *S. pneumoniae*. Patients with two different isolates were counted twice. Example, patients mentioned in footnote nr 1 was counted once for *S. pneumoniae* and once for *H. influenzae*.

Table 2.5 Total number of isolates from CSF and/or blood received in 2013, according to bacterial species and specimen source

Species		**CSF or CSF and blood**	**Blood only**	**Total**	**%**
Neisseria meningitidis		39 [1]	72	111	**7.8**
Haemophilus influenzae		16	144 [2,3]	160	**11.3**
Streptococcus pneumoniae		138	768	906	**64.0**
Escherichia coli		8	18	26	**1.8**
Streptococcus agalactiae		20	52	72	**5.1**
Listeria monocytogenes		6	46	52	**3.7**
Streptococcus pyogenes		9	22	31	**2.2**
Staphylococcus aureus		5	18	23	**1.6**
Coagulase-negative staphylococcus		6 [4]	-	6	**0.4**
Cryptococcus neoformans		6	2	8	**0.6**
Others total		14	6	20	**1.4**
Others	*Neisseria cinerea*	-	1	1	
	Neisseria flavescens	-	1	1	
	Neisseria macacae	-	3	3	
	Klebsiella oxytoca	2	-	2	
	Proteus mirabilis	1	-	1	
	Streptococcus anginosus	1	-	1	
	Streptococcus faecium	1	-	1	
	Streptococcus pseudopneumoniae	3	-	3	
	Streptococcus mitis	1	-	1	
	Enterococcus faecalis	2	-	2	
	Enterococcus faecium	1	-	1	
	Nocardia farcinica	1	-	1	
	Serratia marcescens	1	1	2	
Non viable		-	1 [5]	1	**0.1**
Total		267	1149	1416	**100.0**
%		**18.9**	**81.1**	**100.0**	

1 In one patient *Neisseria meningitides* and *Staphylococcus hominis* were isolated from the CSF
2 In one patient *Streptococcus pneumoniae* and *Haemophilus influenzae* were isolated from the blood
3 In one patient *Haemophilus influenzae* and *Streptococcus agalactiae* were isolated from the blood
4 From 6 Coagulase-negative staphylococcus two were *Staphylococcus epidermidis* and four were *Staphylococcus hominis*
5 Non viable, in one patient a *Streptococcus pneumoniae* was isolated from the blood. The isolate was non viable.

3 BACTERIAL MENINGITIS - general data

In 2013, the Reference Laboratory received CSF isolates of 267 patients. Furthermore, 25 culture-negative CSF samples appeared to be positive by antigen detection or PCR (Table 11.1). Of these CSF samples, 11 were positive for *N. meningitidis,* 13 for *S. pneumoniae* and 1 for *C. neoformans*. Including these cases, the total number of patients with confirmed meningitis amounted to 292. The proportion of meningococcal and pneumococcal meningitis among these patients was 17% and 52%, respectively (Figure 3.1). Of 11 meningococcal and 13 pneumococcal meningitis cases identified by a PCR positive CSF, 3 had a meningococcal isolate from the blood and 8 a pneumococcal isolate from the blood, respectively.



Figure 3.1 *Proportional distribution of CSF isolates and CSF positive samples, 2013*

Figure 3.2 shows the annual total number of bacterial isolates from CSF during the period 2004-2013. The 10 years trend line indicates a decrease over the last decade. The incidence per 100,000 inhabitants also shows a decreasing trend and varied between 3.4 and 1.6 during the period 2004-2013 (Figure 3.2).
Data concerning *N. meningitidis, H. influenzae* and *S. pneumoniae* during the same period are presented in figure 3.3. Since the introduction of vaccination against *H. influenzae* type b in 1993, the incidence of Haemophilus meningitis decreased to 0.10 per 100,000 and remained at this low level. The number of cases of meningococcal meningitis (with an isolate) decreased from 480 cases (incidence of 3.1) in 1993 to 39 cases (incidence of 0.2) in 2013, mainly due to a decline in the number of cases of serogroup B and C meningitis. Nationwide vaccination against serogroup C meningococci was started in 2002. The year 2003 was the first year, since two decades, in which *N. meningitidis* was not the main cause of bacterial meningitis in the Netherlands. Pneumococcal meningitis was slowly increasing since 1991 as the annual incidence rose from 1.0 to 1.6 per 100,000 inhabitants in 2004, but had decreased to 0.8 in 2013 due to vaccination against pneumococci introduced in June

2006 in the National Immunisation Programme.



Figure 3.2 *Isolates from CSF, 2004-2013*



Figure 3.3 *Meningococcal, Haemophilus and pneumococcal meningitis, 2004-2013*

Table 3.1 shows the frequency of isolation of the different bacterial species from CSF by annual quarter. In previous years, most strains were received during the first quarter of the year. Last year (2013) we received most strains in the first quarter.

Table 3.1 Isolates from CSF by annual quarter, 2013

	ANNUAL QUARTER					
SPECIES	**first**	**second**	**third**	**fourth**	**Total**	**%**
N. meningitidis	19	9	6	5	39	**14.6**
H. influenzae	3	5	2	6	16	**6.0**
S. pneumoniae	65	33	18	22	138	**51.7**
E. coli	-	3	3	2	8	**3.0**
S. agalactiae	7	5	3	5	20	**7.5**
L. monocytogenes	1	-	3	2	6	**2.2**
S. pyogenes	7	-	1	1	9	**3.4**
S. aureus	2	2	1	-	5	**1.9**
Coag.neg.Staph.	3	-	1	2	6	**2.2**
C. neoformans	1	-	3	2	6	**2.2**
Others	2	2	4	6	14	**5.3**
non viable	-	-	-	-	-	**-**
Total	110	59	45	53	267	**100.0**
%	**41.2**	**22.1**	**16.9**	**19.8**	**100.0**	

Tables 3.2 and 3.3 show the distribution of the bacterial species isolated from CSF according to the age of the patient and the age-specific incidence per 100,000, respectively. *Streptococcus agalactiae* is still the predominant species isolated in neonates (younger than 1 month), and represented 58% of the isolates in this age group, whereas in the age group 1-11 months the predominant species were *S. pneumoniae* and *N. meningitidis* (together 70%). Since the introduction of the vaccine against *H.influenzae* type b, the number of cases of *H.influenzae* meningitis in the age group 0-4 year has strongly decreased (1992: 231; 2004: 17 and 2013: 10).

Table 3.2 Isolates from CSF grouped according to patients' age, 2013

	AGE (MONTHS)			AGE (YEARS)											
SPECIES	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	**Total**	**%**
N. meningitidis	-	11	7	18	3	-	2	5	-	3	5	3	-	39	**14.6**
H. influenzae	-	4	6	10	-	-	-	-	1	-	3	2	-	16	**6.0**
S. pneumoniae	1	8	2	11	4	-	-	4	7	18	39	46	9	138	**51.7**
E. coli	6	-	-	6	-	-	-	-	1	-	1	-	-	8	**3.0**
S. agalactiae	14	3	1	18	-	-	-	-	-	-	2	-	-	20	**7.5**
L. monocytogenes	1	-	-	1	-	-	-	1	-	-	2	2	-	6	**2.2**
S. pyogenes	-	-	-	-	1	-	-	-	3	2	2	1	-	9	**3.4**
S. aureus	-	-	-	-	-	1	1	-	-	-	1	2	-	5	**1.9**
Coag.neg.Staph.	-	-	1	1	-	-	-	-	1	1	1	2	-	6	**2.2**
C. neoformans	-	-	-	-	-	-	-	-	-	2	2	2	-	6	**2.2**
Others	2	1	-	3	-	-	-	1	1	1	5	2	1	14	**5.3**
non viable	-	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**
Total	24	27	17	68	8	1	3	11	14	27	63	62	10	267	**100.0**
%	**9.0**	**10.1**	**6.4**	**25.5**	**3.0**	**0.4**	**1.1**	**4.1**	**5.2**	**10.1**	**23.6**	**23.2**	**3.8**	**100.0**	

As anticipated from table 3.2, the incidence of bacterial meningitis was highest in the age group of 0 years (table 3.3).

Table 3.3 Age-specific incidence of bacterial meningitis per 100,000 inhabitants grouped according to species, 2013

	AGE (YEARS)											
SPECIES	**0**	**1-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	**Total**
N. meningitidis	6.26	0.95	0.32	-	0.20	0.24	-	0.12	0.15	0.14	-	0.23
H. influenzae	2.28	0.81	-	-	-	-	0.05		0.09	0.09	1.28	0.10
S. pneumoniae	5.13	0.27	0.42	-	-	0.19	0.34	0.70	1.15	2.17	-	0.82
E. coli	3.42	-	-	-	-	-	0.05		0.03	-	-	0.05
S. agalactiae	9.68	0.14	-	-	-	-	-	-	0.06	-	-	0.12
L. monocytogenes	0.57	-	-	-	-	0.05	-	-	0.06	0.09	-	0.04
S. pyogenes	-	-	0.11	-	-	-	0.15	0.08	0.06	0.05	-	0.05
S. aureus	-	-	-	0.10	0.10	-	-	-	0.03	0.09	-	0.03
Coag.neg.Staph.	-	0.14	-	-	-	-	0.05	0.04	0.03	0.09	-	0.04
C. neoformans	-	-	-	-	-	-	-	0.08	0.06	0.09	-	0.04
Others	1.71	-	-	-	-	0.05	0.05	0.04	0.15	0.09	0.14	0.08
non viable	-	-	-	-	-	-	-	-	-	-	-	-
Total	29.05	2.31	0.84	0.10	0.30	0.53	0.69	1.05	1.85	2.92	1.42	1.59

Table 3.4 shows the frequency of the isolates per species from CSF according to gender of the patients. For most species the Male/Female ratio varied between 0.5 and 1.5. The M/F ratio among patients infected with *C. neoformans* was 5.0. The overall M/F ratio was 1.1.

Table 3.4 Isolates from CSF according to patients' gender, 2013

SPECIES	**M**	**F**	**M/F-ratio**	**sex not known**	**Total**	**%**
N. meningitides	20	19	**1.1**	-	39	**14.6**
H. influenzae	6	10	**0.6**	-	16	**6.0**
S. pneumoniae	73	64	**1.1**	1	138	**51.7**
E. coli	4	4	**1.0**	-	8	**3.0**
S. agalactiae	12	8	**1.5**	-	20	**7.5**
L. monocytogenes	3	3	**1.0**	-	6	**2.2**
S. pyogenes	4	5	**0.8**	-	9	**3.4**
S. aureus	2	2	**1.0**	1	5	**1.9**
Coag.neg.Staph.	2	4	**0.5**	-	6	**2.2**
C. neoformans	5	1	**5.0**	-	6	**2.2**
Others	8	6	**1.3**	-	14	**5.3**
non viable	-	-	**-**	-	-	**-**
Total	139	126	**1.1**	2	267	**100.0**
%	**52.1**	**47.2**		**0.7**	**100.0**	

4 NEISSERIA MENINGITIDIS

4.1 General features

In 2013, the Reference Laboratory received 111 *Neisseria meningitidis* isolates, of which 39 were isolated from CSF (or CSF and blood) (41 in 2012) and 72 from blood only (40 in 2012). This means that 65% of cases of meningococcal disease concerned patients with a positive blood culture only, either because no meningitis was present or because no CSF specimen was obtained. The distribution of isolates according to month of receipt shows in previous years that the highest number of isolates was received in the first quarter of the year (figure 4.1). In 2013, this peak was higher than in 2009-2012 in 2013 there was.



Figure 4.1 *Seasonal distribution of meningococcal disease, 2004-2013*

4.2 Antibiotic susceptibility

Seventy-nine percent of all isolates (88/111) were susceptible to penicillin (MIC ≤ 0.064 µg/ml; CSF isolates 90%, isolates from blood only 74%). This higher than in the previous year, but lower than in the years before 2011. (65% in 2012; 70% in 2011; 83% in 2010 and 92% in 2009). This reduced proportion of penicillin-susceptible isolates is mainly due to a doubling of the number of intermediate susceptible isolates (table 4.1, 4.2 and 4.3). In general, mutations in *penA* encoding a penicillin binding protein confers the meningococcus to reduced penicillin susceptibility. Nucleotide sequence analyses of *penA*, confirmed the increase of the number of reduced penicillin susceptible meningococcal isolates. All isolates were susceptible to rifampicin.

Table 4.1 Susceptibility of *N. meningitidis* CSF and/or blood isolates to penicillin, 2013

	Penicillin*					
	MIC ≤ 0.064 sensitive	**0.064< MIC≤0.25**	**0.25< MIC≤1.0**	**MIC >1.0**	**Total**	**%**
CSF or CSF and blood	35	3	1	-	39	**35**
Blood only	53	18	**1**	-	72	**65**
Total number of isolates	88	21	2	-	111	**100**
%	**79**	**19**	**2**	**-**	**100**	

* MIC values in µg/ml

Table 4.2 Susceptibility of *N. meningitidis* isolated from CSF or CSF and blood to penicillin, 2009-2013

	Penicillin*								
	MIC ≤ 0.064 sensitive		**0.064< MIC≤0.25**		**0.25< MIC≤1.0**		**MIC >1.0**		**Total**
	n	%	n	%	n	%	n	%	
2009	51	**98.1**	1	**1.9**	**-**	**-**	-	-	52
2010	43	**81.1**	10	**18.9**	**-**	**-**	-	-	53
2011	29	**78.4**	8	**21.6**	**-**	**-**	-	-	37
2012	24	**58.5**	16	**39.0**	1	**2.4**	-	-	41
2013	35	**89.7**	3	**7.7**	1	**2.6**	-	-	39

* MIC values in µg/ml

Table 4.3 Susceptibility of *N. meningitidis* isolated from blood only to penicillin, 2009-2013

	Penicillin*								
	MIC ≤ 0.064 sensitive		**0.064< MIC≤0.25**		**0.25< MIC≤1.0**		**MIC >1.0**		**Total**
	n	%	n	%	n	%	n	%	
2009	77	**88.5**	10	**11.5**	**-**	-	-	**-**	87
2010	67	**84.8**	12	**15.2**	**-**	-	-	**-**	79
2011	34	**64.2**	19	**35.9**	**-**	-	-	**-**	53
2012	27	**67.5**	13	**32.5**	**-**	-	-	**-**	40
2013	53	**73.6**	18	**25.0**	1	**1.4**	-	**-**	72

* MIC values in µg/ml

4.3 Serogroups

Serogroup B accounted for 75% (2012: 80%) of all isolates and group Y for about 14% (table 4.4). The proportion of serogroup Y isolates is gradually increasing since 2008 (2012: 12%; 2011: 17%; 2010: 8% and 2009: 5%), partly due to a decrease in the number of serogroup B isolates and to a small increase in the number of serogroup Y isolates. The remaining 11% of the isolates were of the rare serogroups C, W or E. The serogroup distribution observed during the whole collection period 1959 - 2013 (figure 4.2) shows that in 2012 the number of group B isolates (83 cases) was the lowest since 1976. In 2013, the number of group B isolates was higher than that in 2012. The proportion of group C isolates was 24% in 1991, decreased to about 10% in 1994 and was since then increasing, with a sharp rise from 19% (105 cases) in 2000 to 40% (276 cases) in 2001 (figure 4.2 and figure 4.2.1). In June 2002, vaccination against serogroup C was included in the National Immunisation Programme. Since then, the number of serogroup C isolates received by the Reference Laboratory rapidly decreased to only a few isolates per year; in 2013 only 6 serogroup C isolates were received (figure 4.3).



Figure 4.2. *Distribution of meningococcal serogroups A, B and C, 1959-2013*



Figure 4.2.1 *Distribution of meningococcal serogroups W, E and Y, 1985-2013*



Figure 4.3 *Bimonthly distribution of meningococcal serogroups B and C, 2002-2013*

4.4 Serogroup and age

The age distribution of patients with meningitis and/or meningococcemia shows that 35% (39 of 111) of the patients was younger than 5 years (table 4.4, figure 4.4). Among patients from whom meningococci were isolated from blood only, 29% was younger than 5 years (table 4.7).

Table 4.4 Serogroups of *N. meningitidis* (all isolates: from CSF and /or blood, absolute numbers) by patient age, 2013

	AGE (MONTHS)			AGE (YEARS)										
SEROGROUP	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-49**	**50-64**	**≥65**	**Total**	**%**
B	-	17	18	35	5	4	6	5	4	6	12	6	83	**74.8**
C	-	-	1	1	-	-	-	-	1	1	-	3	6	**5.4**
Y	-	1	1	2	-	1	1	-	-	2	1	8	15	**13.5**
W	-	1	-	1	-	-	1	-	-	-	-	4	6	**5.4**
E	-	-	-	-	-	-	1	-	-	-	-	-	1	**0.9**
Total	-	19	20	39	5	5	9	5	5	9	13	21	111	**100.0**
%	**-**	**17.1**	**18.0**	**35.1**	**4.5**	**4.5**	**8.1**	**4.5**	**4.5**	**8.1**	**11.7**	**19.0**	**100.0**	

Table 4.5 Serogroups of *N. meningitidis* (isolates from CSF, or CSF and blood; absolute numbers) by patient age, 2013

	AGE (MONTHS)			AGE (YEARS)										
SEROGROUP	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-49**	**50-64**	**≥65**	**Total**	**%**
B	-	11	7	18	3	-	2	4	-	3	5	2	37	**94.8**
C	-	-	-	-	-	-	-	-	1	-	-	-	1	**2.6**
Y	-	-	-	-	-	-	-	-	-	-	-	1	1	**2.6**
W	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**
E	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**
Total	-	11	7	18	3	-	2	4	1	3	5	3	39	**100.0**
%	**-**	**28.2**	**19.9**	**46.1**	**7.7**	**-**	**5.1**	**10.3**	**2.6**	**7.7**	**12.8**	**7.7**	**100.0**	

Table 4.6 Age distribution of meningitis (incidence per 100,000 inhabitants) by different serogroups of *N. meningitidis* (isolates from CSF, or CSF and blood), 2013

	AGE (YEARS)										
SEROGROUP	**0**	**1-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-49**	**50-64**	**≥65**	**Total**
B	6.26	0.95	0.32	-	0.20	0.38	-	0.07	0.15	0.07	0.22
C	-	-	-	-	-	-	0.10	-	-	-	0.01
Y	-	-	-	-	-	-	-	-	-	0.04	0.01
W	-	-	-	-	-	-	-	-	-	-	-
E	-	-	-	-	-	-	-	-	-	-	-
Total	6.26	0.95	0.32	-	0.20	0.38	0.10	0.07	0.15	0.11	0.23

Table 4.7 Serogroups of *N. meningitidis* (isolates from blood only*, absolute numbers) by patient age, 2013

	AGE (MONTHS)			AGE (YEARS)										
SEROGROUP	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-49**	**50-64**	**≥65**	**Total**	**%**
B	-	6	11	17	2	4	4	1	4	3	7	4	46	**64.0**
C	-	-	1	1	-	-	-	-	-	1	-	3	5	**6.9**
Y	-	1	1	2	-	1	1	-	-	2	1	7	14	**19.4**
W	-	1	-	1	-	-	1	-	-	-	-	4	6	**8.3**
E	-	-	-	-	-	-	1	-	-	-	-	-	1	**1.4**
Total	-	8	13	21	2	5	7	1	4	6	8	18	72	**100.0**
%	**-**	**11.1**	**18.1**	**29.2**	**2.8**	**6.9**	**9.7**	**1.4**	**5.6**	**8.3**	**11.1**	**25.0**	**100.0**	

* From 3 patients with a meningococci isolated from blood, CSF was culture-negative but PCR was positive for meningococcal DNA. Cases were in age groups 0-4 (2; B and Y), 50-64 years (1;Y)

Table 4.8 Age distribution of meningococcemia (incidence per 100,000 inhabitants) by different serogroups of *N. meningitidis* (isolates from blood only), 2013

	AGE (YEARS)										
SEROGROUP	**0**	**1-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-49**	**50-64**	**≥65**	**Total**
B	-	2.31	0.21	0.39	0.40	0.09	0.39	0.07	0.21	0.14	0.27
C	-	0.14	-	-	-	-	-	0.02	-	0.11	0.03
Y	-	0.27	-	0.10	0.10	-	-	0.04	0.03	0.25	0.08
W	-	0.14	-	-	0.10	-	-	-		0.14	0.04
E	-	-	-	-	0.10	-	-	-	-	-	0.01
Total	-	2.85	0.21	0.49	0.71	0.09	0.39	0.13	0.24	0.64	0.43

4.5 Group B meningococci

Figure 4.4 shows the age distribution of group B meningococcal disease. The age-specific incidences per 100,000 inhabitants in the age groups younger than 5 years, 15 - 19 years and 50 – 54 years were 3.8, 0.6 and 0.5 respectively. The age-specific incidences per 100,000 inhabitants in the age groups >10 years was less than 0.5 except for the age group 90-94 years (incidence of 2.3).



Figure 4.4 *Age distribution of serogroup B meningococcal disease in 2013*

4.6 Distribution of PorA genosubtypes among serogroup B and C meningococci

The monoclonal antibodies used for (sub)typing of meningococci are no longer available. Therefore, from January 1, 2005 on, typing of meningococcal isolates using monoclonal antibodies is not performed anymore by the Reference Laboratory. Instead, epitopes of PorA and FetA are determined by sequencing of their DNA coding regions.

The epitopes of PorA that react with the monoclonal antibodies of the subtyping scheme are encoded by the variable regions VR1 and VR2 of *porA*, encoding the outer membrane protein PorA. Since 2000 we routinely sequence the DNA regions which encode VR1 and VR2 of PorA of all meningococcal isolates. The DNA sequences are translated into putative amino acid sequences, which are then compared with the PorA epitopes present in the database available on the website: http://neisseria.org/nm/typing/pora/.

In 2013, 39 different VR1/VR2 combinations were encountered among serogroup B meningococci (2010: 36; 2011: 32; 2012: 31). The proportion of the dominant PorA genosubtype P1.7-2,4 decreased from 40% of all serogroup B isolates in 2000 to 8.4% in 2013 (figure 4.5, figure 4.7; table 4.9).

The six serogroup C isolates had the 5 differtent VR1/VR2 combinations. P1.18-1,3, P1.22,9, P1.5,2, P1.5-1,10-8 and P1.7-1,15 respectively.



Figure 4.5 *Distribution of group B meningococcal PorA types, 2013*

Table 4.9 *N. meningitidis* serogroup B isolates according to PorA genosubtype, 2009-2013

	VR1,VR2 combination	YEAR									
		2009		2010		2011		2012		2013	
		No.	%	No.	%	No.	%	No.	%	No.	%
Vaccine types*	1.5-1, 2-2	-	-	1	0.9	-	-	-	-	-	-
	1.5-1, other	3	2.6	3	2.8	1	1.4	3	4.6	1	1.2
	1.5-2,10	11	9.4	11	10.1	2	2.9	4	6.2	7	8.4
	1.5-2, other	4	3.4	3	2.8	3	4.4	-	-	-	-
	1.7,16	4	3.4	2	1.8	1	1.4	-	-	1	1.2
	1.7, other	2	1.7	2	1.8	4	5.8	1	1.5	5	6.0
	1.7-1, 1	2	1.7	3	2.8	2	2.9	2	3.1	-	-
	1.7-1, other	-	-	-	-	-	-	-	-	-	-
	1.7-2,4	28	23.9	24	22.0	10	14.5	6	9.2	7	8.4
	1.7-2, other	15	12.8	7	6.4	4	5.8	8	12.3	13	15.7
	1.12-1, other	6	5.1	4	3.7	1	1.4	1	1.5	1	1.2
	1.18-1,3	1	0.9	2	1.8	2	2.9	1	1.5	3	3.6
	1.18-1, other	3	2.6	2	1.8	2	2.9	5	7.7	3	3.6
	1.19,15-1	-	-	-	-	1	1.4	-	-	3	3.6
	1.19, other	4	3.4	7	6.4	2	2.9	4	6.2	3	3.6
	1.22,14	13	11.1	20	18.3	14	20.3	12	18.5	9	10.9
	1.22,other	7	6.0	4	3.7	5	7.3	8	12.3	6	7.3
	Other, 14	2	1.7	3	2.8	2	2.9	-	-	2	2.4
	Other, 16	5	4.3	2	1.8	3	4.4	2	3.1	3	3.6
	Subtotal vaccine types	110	94.0	100	91.7	59	85.5	57	87.7	67	80.7
NVT**	Other	7	6.0	9	8.3	10	14.5	8	12.3	16	19.3
	Subtotal Non	7		9		10		8		16	
	Total	117	100.0	109	100.0	69	100.0	65	100.0	83	100.0

*based on a nonavalent PorA vaccine, NonaMen; serosubtypes P1.7,16; P1.5-1,2-2; P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1 and P1.18-1,3,6

**Non vaccine type

4.7 Distribution of FetA genosubtypes among serogroup B and C meningococci

In addition to sequencing of PorA epitopes, meningococcal isolates are also characterized by sequencing of an epitope of FetA. This outer membrane protein is involved in iron uptake by meningococci and is considered as a potential vaccine component. Therefore, the variability of this protein has been investigated intensively. The most variable part of the protein, called VR, has been used to establish a typing scheme. Analogous to PorA typing, the VR part of *fetA* is sequenced and translated to a putative aminoacid sequence. So far, about 270 VR sequences comparising 6 classes, are identified, available at
http://neisseria.org/perl/agdbnet/agdbnet.pl?file=fetavr.xml
As an example of a type designation: F5-2, in which the first digit indicates the class and the second digit the variant of this class.

In 2013, 23 different FetA variants were observed among serogroup B meningococci. The dominant type is F1-5, accounting for 21% of group B meningococci (figure 4.6 and 4.7; table 4.10). In previous years this FetA type was strongly linked with PorA VR1/VR2 P1.7-2,4 and together to the MLST clonal complex ST41/44. In 2013, the diversity among the meningococcal isolates was much larger; 17 F1-5 types were linked with 14 different PorA types. FetA F1-5 was 5 times linked with PorA VR1/VR2 P1.7-2 (4 in 2012; 8 in 2011; 20 in 2010).

The 6 serogroup C meningococci had the FetA types F1-5 (once), F3-3 (twice), F3-6 (twice) and F3-9 also once.



Figure 4.6 *Distribution of group B meningococcal FetA genosubtypes, 2013*

Table 4.10 *N. meningitidis* serogroup B isolates according to FetA genosubtype, 2009-2013

	YEAR									
	2009		2010		2011		2012		2013	
FetA type	**No.**	**%**	**No.**	**%**	**No.**	**%**	**No.**	**%**	**No.**	**%**
F1-5	39	**33.3**	36	**33.0**	17	**24.6**	23	**35.4**	17	**20.5**
F1-7	5	**4.3**	12	**11.0**	4	**5.8**	2	**3.1**	6	**7.2**
F1-15	3	**2.6**	2	**1.8**	1	**1.5**	1	**1.5**	1	**1.2**
F3-3	10	**8.5**	4	**3.7**	6	**8.7**	4	**6.2**	6	**7.2**
F3-7	2	**1.7**	1	**0.9**	2	**2.9**	-	**-**	-	**-**
F3-9	2	**1.7**	1	**0.9**	3	**4.3**	3	**4.6**	2	**2.4**
F4-1	4	**3.4**	4	**3.7**	-	**-**	2	**3.1**	2	**2.4**
F5-1	19	**16.2**	20	**18.3**	8	**11.6**	7	**10.8**	14	**16.9**
F5-2	5	**4.3**	-	**-**	2	**2.9**	-	**-**	2	**2.4**
F5-5	12	**10.3**	13	**12.0**	10	**14.5**	11	**16.9**	8	**9.7**
F5-8	3	**2.6**	2	**1.8**	-	**-**	1	**1.5**	-	**-**
F5-12	3	**2.6**	1	**0.9**	2	**2.9**	2	**3.1**	-	**-**
Other	10	**8.5**	13	**12.0**	14	**20.3**	9	**13.8**	25	**30.1**
Total	117	**100.0**	109	**100.0**	69	**100.0**	65	**100.0**	83	**100.0**

In 2013, 39 different VR1/VR2 combinations and 23 different FetA variants were encountered among serogroup B meningococci. Among the dominant FetA type F1-5, accounting for 20% of group B meningococci, 5 were of P1.7-2,4:F1-5 (6% of group B meningococci).
Other frequently found combinations are P1.5-2,10:F5-1 (6%) and P1.22,14:F5-5 (8%) (Figure 4.7).



Figure 4.7 *Distribution of group B meningococcal PorA and FetA geno(sub)types, 2013*

5 *HAEMOPHILUS INFLUENZAE*

5.1 General features

In total, 160 *Haemophilus influenzae* isolates were submitted to the Reference Laboratory. This number is higher than that of the last years (table 2.3, figure 3.3, figure 5.1). Sixteen strains were isolated from CSF (or CSF and blood) (2012: 16; 2011: 13; 2010: 17), and 144 from blood only. Twenty-nine (18%) of the isolates were *H. influenzae* type b (table 5.1). From 1999 to 2004, the number of *H. influenzae* type b isolates received by the Reference Laboratory increased, but decreased after 2004. (table 5.4). The higher number of *H. influenzae* type b isolates was mainly due to an increase of *H. influenzae* type b cases among elderly people.



Figure 5.1 *Distribution of H. influenzae, 2004-2013*

5.2 Antibiotic susceptibility

The proportion of ß-lactamase producing invasive H. influenzae isolates (CSF and/or blood) was decreasing since 2004 and reached a remarkable low value of less than 1% in 2008. 2010 shows the highest value (14.8%) in 25 years. During the history of the Reference Laboratory the proportion has always fluctuated. The reason for this fluctuation is unknown.



Figure 5.2 *Percentage β-lactamase producing H. influenzae, 1994-2013*

5.3 Serotype and age

Nine cases of *H. influenzae* type b invasive disease were observed among children younger than 2 years of age (3 in 2012; 3 in 2011; 6 in 2010; 8 in 2009 and 4 in 2008) (figure 5.3). In total 115 non-typable *H.influenzae* were received; 6 isolated from CSF (or CSF and blood) and 109 isolated from blood only (table 5.1, 5.2 and 5.3). Non-typable strains were isolated more frequently than type b isolates (table 5.1).

Table 5.1 Total number of *H.influenzae isolates* from CSF and/or blood, according to serotype and age, 2013

	AGE (MONTH)				AGE (YEAR)					TOTAL	
TYPE	**0**	**1- 11**	**12-23**	**24-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
b	-	6	3	4	13	1	-	4	11	29	**18.1**
e	-	-	-	-	-	-	-	-	3	3	**1.9**
f	-	1	-	-	1	-	-	-	12	13	**8.1**
n.t.*	3	1	2	2	8	1	2	12	92	115	**71.9**
Total	3	8	5	6	22	2	2	16	118	160	**100.0**
%	**1.9**	**5.0**	**3.1**	**3.7**	**13.7**	**1.3**	**1.3**	**10.0**	**73.7**	**100.0**	

* non-typable

Table 5.2 *H.influenzae* isolates from CSF (or CSF and blood), according to serotype and age, 2013

	AGE (MONTH)				AGE (YEAR)					TOTAL	
TYPE	**0**	**1- 11**	**12-23**	**24-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
b	-	3	2	2	7	-	-	-	1	8	**50.0**
e	-	-	-	-	-	-	-	-	1	2	**12.5**
f	-	1	-	-	1	-	-	-	-	-	**-**
n.t.*	-	-	1	1	2	-	-	1	3	6	**37.5**
Total	-	4	3	3	10	-	-	1	5	16	**100.0**
%	**-**	**25.0**	**18.75**	**18.75**	**62.5**	**-**	**-**	**6.2**	**31.3**	**100.0**	

* non-typable

Table 5.3 *H. influenzae* isolates from blood only, according to serotype and age, 2013

	AGE (MONTH)				AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-23**	**24-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
b	-	3	1	2	6	1	-	4	10	21	**14.6**
e	-	-	-	-	-	-	-	-	3	3	**2.1**
f	-	-	-	-	-	-	-	-	11	11	**7.6**
n.t.*	3	1	1	1	6	1	2	11	89	109	**75.7**
Total	3	4	2	3	12	2	2	15	113	144	**100**
%	**2.1**	**2.7**	**1.4**	**2.1**	**8.3**	**1.4**	**1.4**	**10.4**	**75.5**	**100.0**	

* non-typable



Figure 5.3 *Age distribution of H. influenzae type b invasive disease in the first two years of life, 1992-2013*

5.4 Distribution of non-typable H. influenzae

The proportion of non-typable isolates increased from 6% in 1992 to about 70% from 1997 onwards (table 5.4). In 2013 the proportion of non-typable isolates was 72%.

Table 5.4 *H. influenzae* isolates from CSF and/or blood received from 1992 to 2013 according to year and serotype

	SEROTYPE						TOTAL		CSF (or CSF and blood)	Blood Only
YEAR	a	b	d	e	f	n.t.*	Total	% n.t.*		
1992	-	294	-	-	1	20	315	**6.3**	241	74
1993	-	244	1	1	3	28	277	**10.1**	204	73
1994	-	148	-	-	2	26	176	**14.8**	112	64
1995	-	60	-	-	-	36	96	**37.5**	50	46
1996	-	30	-	-	6	52	88	**59.1**	28	60
1997	-	19	-	1	6	59	85	**69.4**	22	63
1998	-	19	1	-	5	63	88	**71.6**	31	57
1999	-	12	-	1	1	55	69	**79.7**	23	46
2000	4	15	1	2	4	48	74	**64.9**	24	50
2001	-	17	-	2	8	63	90	**70.0**	19	71
2002	-	31	-	1	13	63	108	**58.3**	28	79
2003	-	31	-	-	8	90	129	**69.8**	27	102
2004	-	48	-	2	4	71	125	**56.8**	32	93
2005	1	41	-	2	10	78	132	**59.1**	37	95
2006	-	24	-	4	7	85	120	**70.8**	25	95
2007	-	24	-	2	2	87	115	**75.7**	19	97
2008	-	25	-	-	11	72	108	**66.7**	19	89
2009	-	32	1	3	9	84	129	**65.1**	15	114
2010	1	37	-	3	5	96	142	**67.6**	17	125
2011	-	22	-	8	11	98	139	**70.5**	13	126
2012	1	28	-	2	8	101	140	**72.1**	16	124
2013	-	29	-	3	13	115	160	**71.9**	16	144

* non-typable

The absolute number of non-typable isolates from CSF remained stable during the period 1992 to 2006, but decreased somewhat from then on as shown in figure 5.4. In 20123the number of non-typable isolates from CSF was half the number of 2012, but similar to that of the years before 2012. The number of non-typable *H. influenzae* isolates from blood increased during the period 1992 to 2013 from 15 to 89 (figure 5.4).



Figure 5.4 *Non-typable H. influenzae isolates from CSF and/or blood received from 1993-2013*

Table 5.5 Non-typable *H. influenzae* isolates from CSF and/or blood received from 2004 to 2013 according to year and biotype.

	Biotype							
YEAR	**I**	**II**	**III**	**IV**	**V**	**VI**	**VII**	**Total**
2004	11	29	23	2	6	-	-	71
2005	7	48	16	1	5	1	-	78
2006	11	44	25	3	2	-	-	85
2007	12	47	19	1	7	1	-	87
2008	16	29	18	3	5	1	-	72
2009	28	30	12	10	3	1	-	84
2010	20	49	19	2	6	-	-	96
2011	27	41	24	3	2	1	-	98
2012	25	49	17	2	6	1	1	101
2013	25	44	30	7	7	2	-	115

* non-typable

Among non-serotypable *H. influenzae* isolates biotype II was the predominant biotype during the last ten years.

6 *STREPTOCOCCUS PNEUMONIAE*

6.1 General features

The Reference Laboratory received 906 *S. pneumoniae* isolates. Of these, 138 were isolated from CSF or from CSF and blood (table 2.3; figure 6.1). The incidence of pneumococcal meningitis slightly rose since 1990 from 1.0 to 1.6 in 2004; due to vaccination with the hepta-valent polyscaccharide conjugate vaccine it slightly decreased to 0.8 in 2013. A steep increase in the number of pneumococcal blood isolates had occurred between 1994 (312 isolates) and 2003 (1471 isolates). This increase can be explained by the increasing use of automated blood culture devices by the contributing laboratories and by a real increase in the number of cases of pneumococcal bacteremia due to pneumonia among patients of the increasing cohort of the elderly (figure 6.1) and by a more complete submission of isolates by the laboratories.
The number of isolates from blood sent to the Reference Laboratory decreased from 1471 in 2003 to 768 in 2013. This was due to a change in policy: from 2003 onwards, we asked only nine sentinel laboratories, evenly distributed over the country, to send pneumococcal blood isolates. Thus, the numbers of *S. pneumoniae* from blood only are incomplete.

This policy has been changed to monitor the effect of the introduction of the 7-valent conjugate pneumococcal polysaccharide vaccine by June 1st, 2006. In April 2011 the 10-valent vaccine was introduced for all newborns born March 1, 2011. From 2006 onwards, all laboratories are requested to send all invasive pneumococcal isolates from patients in the age group 0-4 year, while from patients older than 4 year only isolates from CSF are requested. Again, from nine sentinel laboratories we ask all invasive pneumococcal isolates from all patients.



Figure 6.1 *Distribution of S. pneumoniae isolates, 1994-2013*

6.2 Antibiotic susceptibility

Among 138 isolates from CSF (or CSF and blood) and 768 isolates from the blood only, 2 (0.2%) and 14 (1.5%), respectively, were intermediately susceptible to penicillin (0.06< MIC≤1.0 mg/L, table 6.1). Four (0.4%) strains were resistant to penicillin (MIC > 1.0 mg/L).

Table 6.1 Susceptibility of *S. pneumoniae* isolates to penicillin, 2013

	Penicillin*				
	MIC ≤ 0.06	**0.06< MIC≤1.0**	**MIC >1.0**	**Total**	**%**
CSF or CSF and blood	135	2	1	138	**15.2**
Blood only	751	14	3	768	**84.8**
Total number of isolates	886	16	4	906	**100.0**
%	**97.8**	**1.8**	**0.4**	**100.0**	

* MIC values in µg/ml according to EUCAST guidelines

Figure 6.2 shows the distribution of *S. pneumoniae* isolates according to the patients' age. The incidence of pneumococcal meningitis is highest among patients in the age group 65 – 70 year (Table 6.4).



Figure 6.2 *Distribution of S. pneumoniae isolates received in 2013 according to age*

6.3 Distribution according to serotype

The relationship between age and major types of all isolates is shown in table 6.2. For isolates from CSF (or CSF and blood), the distribution of serotypes by age of the patient is presented in table 6.3, while the incidence of *S. pneumoniae* meningitis per serotype per 100,000 inhabitants is shown in table 6.4. The distribution of serotypes by age of the patient for pneumococcal isolates from blood only is shown in table 6.5. As aforementioned, incidences of *S. pneumoniae* from blood only are incomplete. In the age group 0-4 years the number of cases was lower than that of previous years, mainly because of the lower number of cases due to pneumococci with serotypes included in the deca-valent conjugate vaccine (table 6.2, 6.3 and figure 12.4). Effect of the 10-valent vaccine can also been seen in table 6.6 and table 6.7. There was an overall reduction of the number of isolates from CSF, due to a reduction of the cases due to pneumococci with serotypes included in the vaccine.

The serotype distributions of CSF (or CSF and blood) and blood isolates only, are shown in table 6.5, 6.6 and 6.7. Table 6.6 shows the distribution of CSF isolates according to serotype over the last 10 years. Table 6.7 shows the distribution of blood only isolates from the 9 selected laboratories according to serotype over the last 7 years. From 2006 on those blood isolates were subtyped. After the introduction of the 7-valent polysaccharide conjugate vaccine in the National Immunisation Programme the number of isolates with a vaccine type decreased dramatically. However, the effect was abrogated by an increase of the number of isolates with non-vaccine types, in particular 3, 8, 19A , 22F and 33F (Table 6.6 and 6.7).

Table 6.2 *S. pneumoniae* isolates from CSF and/or blood nation-wide, by serotype and age of patients, 2013

	AGE (MONTHS)			AGE (YEARS)											
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	**Total**	**%**
1	-	-	-	-	4	1	1	-	10	10	14	13	1	54	**6.0**
3	-	1	1	2	2	-	1	2	6	5	15	21	16	71	**7.8**
4	-	-	-	-	-	-	-	2	-	1	9	4	1	17	**1.9**
6	-	1	-	1	1	-	2	1	-	1	5	9	10	30	**3.3**
7	-	3	2	5	1	1	-	1	10	12	29	42	9	110	**12.1**
8	-	-	-	-	2	-	1	3	3	17	44	64	23	157	**17.3**
9	-	-	-	-	-	-	-	-	2	4	7	11	6	30	**3.3**
10	-	4	1	5	-	-	-	2	-	-	5	6	-	18	**2.0**
12	-	-	2	2	1	-	-	1	5	3	6	18	5	41	**4.5**
14	-	-	-	-	-	-	-	1	1	2	2	3	-	9	**1.0**
18	-	1	-	1	-	-	-	-	1	1	2	5	3	13	**1.4**
19	-	7	1	8	1	1	-	1	3	4	22	31	27	98	**10.8**
22	-	1	-	1	1	-	-	-	2	3	16	22	20	65	**7.2**
23	-	1	1	2	-	-	-	-	1	2	5	15	8	33	**3.7**
Others	1	2	5	8	1	1	-	3	7	16	30	61	33	160	**17.7**
Total	1	21	13	35	14	4	5	17	51	81	211	326	162	906	**100.0**
%	**0.1**	**2.4**	**1.4**	**3.9**	**1.5**	**0.4**	**0.6**	**1.9**	**5.6**	**8.9**	**23.3**	**36.0**	**17.9**	**100.0**	

Table 6.3 *S. pneumoniae* isolates from CSF (or CSF and blood) nation-wide, by serotype and age of patients, 2013

	AGE (MONTHS)			AGE (YEARS)											
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	**Total**	**%**
1	-	-	-	-	-	-	-	-	-	1	-	2	-	3	**2.2**
3	-	-	-	-	2	-	-	2	1	1	5	4	1	16	**11.6**
4	-	-	-	-	-	-	-	1	-	-	-	1	-	2	**1.4**
6	-	-	-	-	1	-	-	1	-	1	2	1	1	7	**5.1**
7	-	2	-	2	-	-	-	-	2	2	5	5	-	16	**11.6**
8	-	-	-	-	-	-	-	-	2	2	6	6	-	16	**11.6**
9	-	-	-	-	-	-	-	-	-	2	1	-	-	3	**2.2**
10	-	3	-	3	-	-	-	-	-	-	3	1	-	7	**5.1**
12	-	-	1	1	-	-	-	-	2	2	1	2	1	9	**6.5**
14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**
18	-	-	-	-	-	-	-	-	-	-	1	-	1	2	**1.4**
19	-	1	1	2	1	-	-	-	-	-	3	3	2	11	**8.0**
22	-	-	-	-	-	-	-	-	-	-	4	4	-	8	**5.8**
23	-	1	-	1	-	-	-	-	-	1	2	6	1	11	**8.0**
Others	1	1	-	2	-	-	-	-	-	6	6	11	2	27	**19.5**
Total	1	8	2	11	4	-	-	4	7	18	39	46	9	138	**100.0**
%	**0.7**	**5.8**	**1.5**	**8.0**	**2.9**	**-**	**-**	**2.9**	**5.1**	**13.0**	**28.3**	**33.3**	**6.5**	**100.0**	

Table 6.4 Age-specific incidence of pneumococcal meningitis nation-wide (isolates from CSF or CSF and blood) per 100,000 inhabitants according to type, 2013

	AGE (YEAR)											
TYPE	**0**	**1-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	**Total**
1	-	-	-	-	-	-	-	0.04	-	0.09	-	0.02
3	-	-	0.21	-	-	0.10	0.05	0.04	0.15	0.19	0.14	0.10
4	-	-	-	-	-	0.05	-	-	-	0.05	-	0.01
6	-	-	0.11	-	-	0.05	-	0.04	0.06	0.05	0.14	0.04
7	1.14	-	-	-	-	-	0.10	0.08	0.15	0.24	-	0.10
8	-	-	-	-	-	-	0.10	0.08	0.18	0.28	-	0.10
9	-	-	-	-	-	-	-	0.08	0.03	-	-	0.02
10	1.71	-	-	-	-	-	-	-	0.09	0.05	-	0.04
12	-	0.14	-	-	-	-	0.10	0.08	0.03	0.09	0.14	0.05
14	-	-	-	-	-	-	-	-	-	-	-	-
18	-	-	-	-	-	-	-	-	0.03	-	0.14	0.01
19	0.57	0.14	0.11	-	-	-	-	-	0.09	0.14	0.28	0.07
22	-	-	-	-	-	-	-	-	0.12	0.19	-	0.05
23	0.57	-	-	-	-	-	-	0.04	0.06	0.28	0.14	0.07
Others	1.14	-	-	-	-	-	-	0.23	0.18	0.52	0.28	0.16
Total	5.13	0.27	0.42	-	-	0.19	0.34	0.70	1.15	2.17	1.28	0.82

Table 6.5 All *S. pneumoniae* isolates from blood only* nation-wide, by serotype and age of patients, 2013

	AGE (MONTHS)			AGE (YEARS)											
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	**Total**	**%**
1	-	-	-	-	4	1	1	-	10	9	14	11	1	51	**6.6**
3	-	1	1	2	-	-	1	-	5	4	10	18	15	55	**7.2**
4	-	-	-	-	-	-	-	1	-	1	9	3	1	15	**2.0**
6	-	1	-	1	-	-	2	-	-	-	3	8	9	23	**3.0**
7	-	1	2	3	1	1	-	1	8	10	24	37	9	94	**12.2**
8	-	-	-	-	2	-	1	3	1	15	38	58	23	141	**18.4**
9	-	-	-	-	-	-	-	-	2	2	6	11	6	27	**3.5**
10	-	1	1	2	-	-	-	2	-	-	2	5	-	11	**1.4**
12	-	-	1	1	1	-	-	1	3	1	5	16	4	32	**4.2**
14	-	-	-	-	-	-	-	1	1	2	2	3	-	9	**1.2**
18	-	1	-	1	-	-	-	-	1	1	1	5	2	11	**1.4**
19	-	6	-	6	-	1	-	1	3	4	19	28	25	87	**11.3**
22	-	1	-	1	1	-	-	-	2	3	12	18	20	57	**7.4**
23	-	-	1	1	-	-	-	-	1	1	3	9	7	22	**2.9**
Others	-	1	5	6	1	1	-	3	7	10	24	50	31	133	**17.3**
Total	-	13	11	24	10	4	5	13	44	63	172	280	153	768	**100.0**
%	**-**	**1.7**	**1.4**	**3.1**	**1.3**	**0.5**	**0.7**	**1.7**	**5.7**	**8.2**	**22.4**	**36.5**	**19.9**	**100.0**	

* From 8 patients with a pneumococcus isolated from blood, CSF was culture-negative but PCR was positive for pneumococcal DNA. Cases were in age groups 30-39 (1), 50-64 years (4) and 65-79 years (3)

Table 6.6 Distribution of pneumococcal CSF isolates according to serotype nation-wide, 2004-2013

			TYPE	Year 2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
23-valent vaccine	10-valent vaccine	7-valent	4	15	8	12	5	8	4	3	2	4	2
			6B	28	17	21	12	11	3	-	2	-	-
			9V	10	10	6	10	7	2	2	-	3	1
			14	34	24	28	18	8	3	5	2	1	-
			18C	14	14	19	17	8	6	5	5	2	2
			19F	21	19	15	11	7	10	2	6	4	2
			23F	19	16	16	22	17	5	4	2	1	-
			Subtotal 7-valent vaccine	*141*	*108*	*117*	*95*	*66*	*33*	*21*	*19*	*15*	*7*
			1	7	6	1	8	8	8	3	1	1	3
			5	-	1	1	-	-	-	2	-	3	-
			7F	21	19	18	36	25	25	20	28	16	15
			Subtotal 10-valent vaccine	*168*	*134*	*137*	*139*	*99*	*66*	*46*	*48*	*35*	*25*
			2	-	-	-	-	-	-	-	-	-	-
			3	20	16	20	16	17	24	20	7	13	16
			8	11	15	10	21	9	10	10	17	9	16
			9N	5	10	2	4	1	3	6	7	4	2
			10A	7	6	7	8	7	10	9	7	9	7
			11A	-	5	3	4	2	8	1	5	1	1
			12F	2	1	1	4	2	2	3	7	10	9
			15B	3	3	-	1	4	8	2	3	1	-
			17F	1	-	-	1	-	-	4	3	1	1
			19A	8	7	2	9	8	6	20	16	6	9
			20	2	-	1	-	1	-	1	-	-	1
			22F	4	4	9	2	10	13	14	16	11	8
			33F	2	1	3	5	6	6	7	5	6	3
			Subtotal 23-valent vaccine	*234*	*202*	*195*	*214*	*166*	*156*	*143*	*141*	*106*	*98*
			6A	9	8	5	5	4	6	5	1	1	1
			6C	2	2	1	2	-	-	3	4	2	6
			7B	-	-	-	-	-	-	-	-	-	1
			10F	-	-	-	-	-	-	-	-	-	-
			10B	-	-	-	-	-	-	-	-	1	-
			12A	-	-	-	-	-	-	-	-	-	-
			13	-	1	-	-	-	1	-	-	-	-
			15A	-	-	-	1	1	-	1	1	1	4
			15C	1	2	1	1	3	1	2	-	3	-
			16F	2	4	2	2	2	-	5	4	-	5
			17A	-	-	-	-	-	1	-	-	-	-
			18F	1	1	-	-	-	-	-	-	-	-
			18A	1	-	-	-	-	-	-	-	-	-
			18B	1	1	1	1	1	-	-	-	1	-
			21	1	1	-	1	-	-	-	1	-	-
			22A	1	-	-	1	-	1	1	-	-	-
			23A	3	4	-	3	1	3	3	2	4	4
			23B	2	1	2	2	3	7	5	2	5	7
			24F	-	3	-	3	2	6	1	1	4	4
			24B	-	-	-	-	-	-	-	-	2	-
			25	-	-	-	-	1	-	-	-	-	-
			27	-	-	-	1	2	-	-	-	1	-
			28F	-	-	-	-	-	-	-	-	-	1
			28A	-	1	-	-	-	-	-	1	-	-
			29	1	-	-	-	-	-	-	-	1	-
			31	1	1	2	2	-	1	1	-	1	-
			33A	-	1	-	-	-	-	-	-	-	-
			34	-	-	-	1	1	1	-	1	-	-
			35F	4	-	1	2	2	2	4	1	-	2
			35B	2	1	1	1	-	-	1	-	1	3
			37	-	-	-	-	-	1	-	1	2	1
			38	1	1	1	-	1	3	1	-	2	1
			Rough (n.t.)	1	-	-	-	-	-	-	-	-	-
			Total	268	235	212	243	190	190	176	163	138	138

Table 6.7 Distribution of *S. pneumoniae* from blood only (from the 9 sentinel laboratories), according to serotype, 2006-2013

			TYPE	Year 2006	2007	2008	2009	2010	2011	2012	2013
23-valent vaccine	10-valent vaccine	7-valent	4	52	54	30	26	17	27	11	13
			6B	21	26	25	12	8	3	3	3
			9V	65	53	42	26	21	5	2	4
			14	86	84	54	34	22	19	12	8
			18C	12	13	15	15	7	8	4	8
			19F	19	11	9	10	5	9	3	5
			23F	29	39	13	12	13	5	3	1
			***Subtotal* 7-valent vaccine**	*284*	*280*	*188*	*135*	*93*	*85*	*38*	*42*
			1	25	75	64	65	53	40	50	40
			5	-	3	2	6	7	11	8	9
			7F	75	55	65	86	72	91	92	75
			***Subtotal* 10-valent**	*384*	*413*	*319*	*292*	*225*	*227*	*188*	*166*
			2	-	-	-	-	-	-	-	-
			3	32	30	31	34	30	36	45	40
			8	42	47	46	52	60	59	88	108
			9N	19	13	19	18	19	17	20	19
			10A	6	4	7	9	9	14	8	6
			11A	6	16	3	12	12	9	14	16
			12F	9	5	6	5	13	19	25	22
			15B	5	1	4	6	7	4	1	7
			17F	1	3	1	7	4	8	7	4
			19A	21	25	33	30	57	63	78	61
			20	2	3	3	3	3	4	-	1
			22F	19	18	24	24	29	37	41	45
			33F	10	6	10	11	10	15	22	12
			***Subtotal* 23-valent**	*556*	*584*	*506*	*503*	*478*	*503*	*537*	*507*
			6A	7	10	18	11	9	2	6	2
			6C	-	2	1	7	9	7	10	10
			7C	2	1	-	-	-	-	-	-
			9A	-	-	-	-	-	-	1	-
			10F	-	-	1	-	-	-	-	-
			10B	-	-	-	-	-	-	-	1
			11B	-	1	-	-	-	-	-	-
			12A	-	-	-	-	-	-	-	-
			13	-	-	-	-	-	1	-	-
			15F	-	-	-	-	-	-	-	1
			15A	-	1	1	1	-	2	7	13
			15C	-	1	2	2	1	2	1	4
			16F	6	6	9	8	10	7	6	7
			17A	-	-	-	-	-	2	-	-
			18F	-	-	-	-	-	-	-	-
			18A	-	1	-	1	1	1	-	-
			18B	-	1	-	-	-	-	1	1
			21	-	-	-	-	-	-	-	2
			22A	3	2	1	-	1	1	-	1
			23A	2	6	3	9	7	2	6	6
			23B	1	1	3	6	3	9	3	6
			24F	1	1	7	-	2	3	2	4
			25F	1	-	1	-	-	-	-	-
			27	-	-	1	1	-	1	-	1
			28A	-	-	-	-	-	-	-	-
			29	-	-	-	-	-	-	1	-
			31	1	1	3	1	4	2	6	2
			33A	-	-	-	-	-	-	1	-
			34	1	1	-	1	1	-	1	2
			35F	2	1	2	4	5	6	5	6
			35A	-	-	-	-	-	-	1	-
			35B	3	-	-	4	-	3	1	7
			37	-	1	-	-	1	-	-	-
			38	3	2	3	5	-	3	-	1
			40	-	-	-	-	-	-	-	1
			Rough (n.t.)	2	-	-	-	-	2	-	-
			Total	591	624	562	564	532	559	596	585

Table 6.8 Distribution of *S. pneumoniae* isolates from CSF (or CSF and blood) nation-wide, by serotype and age of patients, 2013.

		TYPE	AGE (YEARS) 0-4	5-9	10-14	15-19	20-29	30-39	40-49	50-64	65-79	≥80	Total	%
23-valent vaccine	10-valent vaccine	7-valent vaccine 4	-	-	-	-	1	-	-	-	1	-	2	**1.45**
		6B	-	-	-	-	-	-	-	-	-	-	-	**-**
		9V	-	-	-	-	-	-	-	1	-	-	1	**0.7**
		14	-	-	-	-	-	-	-	-	-	-	-	**-**
		18C	-	-	-	-	-	-	-	1	-	1	2	**1.45**
		19F	-	1	-	-	-	-	-	-	1	-	2	**1.45**
		23F	-	-	-	-	-	-	-	-	-	-	-	**-**
		Subtotal 7-valent vaccine	-	1	-	-	1	-	-	2	2	1	7	**5.1**
		1	-	-	-	-	-	-	1	-	2	-	3	**2.2**
		5	-	-	-	-	-	-	-	-	-	-	-	**-**
		7F	2	-	-	-	-	1	2	5	5	-	15	**10.9**
		Subtotal 10-valent vaccine	2	1	-	-	1	1	3	7	9	1	25	**18.2**
		2	-	-	-	-	-	-	-	-	-	-	-	**-**
		3	-	2	-	-	2	1	1	5	4	1	16	**11.6**
		8	-	-	-	-	-	2	2	6	6	-	16	**11.6**
		9N	-	-	-	-	-	-	2	-	-	-	2	**1.45**
		10A	3	-	-	-	-	-	-	3	1	-	7	**5.1**
		11A	-	-	-	-	-	-	1	-	-	-	1	**0.7**
		12F	1	-	-	-	-	2	2	1	2	1	9	**6.5**
		15B	-	-	-	-	-	-	-	-	-	-	-	**-**
		17F	-	-	-	-	-	-	-	1	-	-	1	**0.7**
		19A	2	-	-	-	-	-	-	3	2	2	9	**6.5**
		20	-	-	-	-	-	-	1	-	-	-	1	**0.7**
		22F	-	-	-	-	-	-	-	4	4	-	8	**5.8**
		33F	1	-	-	-	-	-	-	1	1	-	3	**2.2**
		Subtotal 23-valent vaccine	9	3	-	-	3	6	12	31	29	5	98	**71.0**
		Other	2	1	-	-	1	1	6	8	17	4	40	**29.0**
		Total	11	4	-	-	4	7	18	39	46	9	138	**100.0**

7 *ESCHERICHIA COLI*

The Reference Laboratory received 26 *Escherichia coli* strains, 8 isolated from CSF (or CSF and blood) and 18 from blood only (table 7.1, 7.2 and 7.3). The number of *E. coli* isolates from CSF was dubbled since 2012 (figure 7.1). Eighty-eight percent of the cases of *E. coli* meningitis occurred in the first month of life.

Interestingly, the types O8, O9, O15 and O171 are prevalent among non-K1 isolates, while the types O non typable, O1, O2, O6, O18, O23, O25, O70, O73, O92 and O117 are more often found among K1 isolates.

Since 2012 all isolates were tested for the H – type. Almost 41% of all K1 isolates were of type H7 (table 7.4)

Table 7.1 Serotypes of *E. coli* isolates from CSF and/or blood, by age of patients, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
Non K1	2	-	-	2	-	-	-	-	2	**8**
K1	21	1	-	22	-	-	1	1	24	**92**
Total	23	1	-	24	-	-	1	1	26	**100**
%	**88**	**4**	**-**	**92**	**-**	**-**	**4**	**4**	**100**	

Table 7.2 Serotypes of *E. coli* isolates from CSF (or CSF and blood), by age of patients, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
Non K1	-	-	-	-	-	-	1	1	2	**25**
K1	6	-	-	6	-	-	-	-	6	**75**
Total	6	-	-	6	-	-	1	1	8	**100**
%	**75**	**-**	**-**	**60**	**-**	**-**	**12.5**	**12.5**	**100**	

Table 7.3 Serotypes of *E. coli* isolates from blood only by age of patients, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
Non K1	2	-	-	2	-	-	-	-	2	**12**
K1	15	1	-	16	-	-	-	-	16	**88**
Total	17	1	-	18	-	-	-	-	18	**100**
%	**94**	**6**	**-**	**100**	**-**	**-**	**-**	**-**	**100**	

Table 7.4 H-type versus K-type of *E. coli* isolates from CSF and/or blood, 2013

TYPE	K1	Non K1	Total
H2	1	-	1
H4	5	-	5
H5	1	-	1
H6	-	1	1
H7	9	-	9
H18	1	-	1
H31	1	-	1
H-rough	1	-	1
H-	3	2	5
H?	-	1	1
Total	22	4	26
%	**85**	**15**	**100**



Figure 7.1 *Distribution of E. coli, 2004-2013*

8 *STREPTOCOCCUS AGALACTIAE* – (group B)

In 2013 the number of *Streptococcus agalactiae* isolates received by the Reference Laboratory decreased to 72 (2012: 80; 2010: 63, figure 8.1). Twenty *S. agalactiae* isolates were from CSF (or CSF and blood) and 52 from blood only (table 8.1, 8.2 and 8.3). Seventy-six percent of the cases occurred in the first month of life. Serotype III was the most prevalent (table 8.1).

Table 8.1 Serotypes of *S. agalactiae* isolates from CSF and/or blood, by age of patients, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
Ia	17	3	-	20	-	-	-	-	20	**27.8**
Ib	6	1	-	7	-	-	-	-	7	**9.7**
II	4	-	-	4	-	-	-	-	4	**5.6**
III	22	7	-	29	-	-	-	1	30	**41.7**
IV	2	1	1	4	-	-	-	1	5	**6.9**
V	2	-	-	2	-	-	-	1	3	**4.2**
n.t.	2	1	-	3	-	-	-	-	4	**4.1**
Total	55	13	1	69	-	-	-	3	72	**100**
%	**76.4**	**18.0**	**1.4**	**95.8**	**-**	**-**	**-**	**4.2**	**100**	

Table 8.2 Serotypes of *S. agalactiae* isolates from CSF (or CSF and blood), by age of patients, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
Ia	4	1	-	5	-	-	-	-	5	**25**
Ib	-	1	-	1	-	-	-	-	1	**5**
II	1	-	-	1	-	-	-	-	1	**5**
III	9	1	-	10	-	-	-	1	11	**20**
IV	-	-	1	1	-	-	-	1	2	**10**
V	-	-	-	-	-	-	-	-	-	**-**
Total	14	3	1	18	-	-	-	4	20	**100**
%	**60**	**15**	**5**	**80**	**-**	**-**	**-**	**20**	**100**	

Table 8.3 Serotypes of *S. agalactiae* isolates from blood only, by age of patients, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
Ia	13	2	-	15	-	-	-	-	15	**28.8**
Ib	6	-	-	6	-	-	-	-	6	**11.5**
II	3	-	-	3	-	-	-	-	3	**5.8**
III	13	6	-	19	-	-	-	-	19	**36.5**
IV	2	1	-	3	-	-	-	-	3	**5.8**
V	2	-	-	2	-	-	-	1	3	**5.8**
n.t.	2	1	-	3	-	-	-	-	3	**5.8**
Total	41	10	-	51	-	-	-	1	52	**100**
%	**78.8**	**19.2**	**-**	**98.0**	**-**	**-**	**-**	**2.0**	**100**	



Figure 8.1 *Distribution of S. agalactiae, 2004-2013*

9 *LISTERIA MONOCYTOGENES*

Fifty-two strains of *Listeria monocytogenes* were submitted to the Reference Laboratory. Six isolates were from CSF (or CSF and blood) and 46 from blood only (figure 9.1). Most cases (92%) occurred among persons older than 50 years. In 2013 (as in previous years) serotypes 1/2a and 4b were most prevalent (table 9.1).

Table 9.1 *L. monocytogenes* isolates from CSF and/or blood, by type and age of patients, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
1/2a	-	-	-	-	-	-	2	19	21	**40**
1/2b	-	-	-	-	-	-	-	7	7	**14**
1/2c	-	-	-	-	-	-	-	1	1	**2**
4b	1	-	-	1	-	-	1	21	23	**44**
Total	1	-	-	1	-	-	3	48	52	**100**
%	**2**	**-**	**-**	**2**	**-**	**-**	**6**	**92**	**100**	

Table 9.2 *L. monocytogenes* isolates from CSF (or CSF and blood), by type and age, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
1/2a	-	-	-	-	-	-	1	1	2	**33**
1/2b	-	-	-	-	-	-	-	1	1	**17**
1/2c	-	-	-	-	-	-	-	-	-	**-**
4b	1	-	-	1	-	-	-	2	3	**50**
Total	1	-	-	1	-	-	1	4	6	**100**
%	**17**	**-**	**-**	**17**	**-**	**-**	**17**	**66**	**100**	

Table 9.3 *L. monocytogenes* isolates from blood only, by serotype and age, 2013

	AGE (MONTH)			AGE (YEAR)					TOTAL	
TYPE	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**	**%**
1/2a	-	-	-	-	-	-	1	18	19	**41**
1/2b	-	-	-	-	-	-	-	6	6	**13**
1/2c	-	-	-	-	-	-	-	1	1	**2**
4b	-	-	-	-	-	-	1	19	20	**44**
Total	1	-	-	1	-	-	1	44	46	**100**
%	**2**	**-**	**-**	**2**	**-**	**-**	**2**	**96**	**100**	



Figure 9.1 *Distribution of L. monocytogenes, 2004-2013*

10 *STREPTOCOCCUS PYOGENES*

Thirty-one *Streptococcus pyogenes* isolates were submitted to the Reference Laboratory, 9 isolated from CSF (or CSF and blood) and 22 from blood only. The latter number was 2-fold higher than in previous years.

The number of isolates from CSF increase since 2012 (figure 10.1).

Table 10.1 *S. pyogenes* isolates from CSF and/or blood received in 2013 according to source of isolation and age

	AGE (MONTH)			AGE (YEAR)					TOTAL
Source	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**Total**
CSF	-	-	-	-	1	-	5	3	9
Blood	-	1	4	5	-	-	2	15	22
Total	-	1	4	5	1	-	7	18	31



Figure 10.1 *Distribution of S. pyogenes, 2004-2013*

11 ANTIGEN AND DNA DETECTION

The Reference Laboratory received 162 culture-negative specimens of CSF, serum or other body fluids for antigen or DNA detection. Polyclonal antibodies were used in latex-agglutination. PCR was performed with primers and probes specific for *N. meningitidis* (targeted on the *ctrA* gene) and for *S. pneumoniae* (targeted on the *pia* gene). When CSF was positive in the meningococcal PCR, it was then subjected to serogroup-specific PCR.

Of 162 specimens, 28 (17 %) were positive by agglutination or PCR. Twelve (11 CSF and 1 other) were positive for *N. meningitidis* and 15 (13 CSF, 1 serum and 1 other) were positive for *S. pneumoniae*.

Thus, in 2013, PCR-positive, culture-negative CSF samples accounted for 22 % of cases of meningococcal meningitis registered in the database of the Reference Laboratory. For *S. pneumoniae*, this percentage was 9%.

Table 11.1 CSF and serum samples, tested for antigens or DNA, 2013

	NUMBER OF SPECIMENS			
	CSF (or CSF and serum)	**Sera**	**Other**	**Total**
Antigen of				
C. neoformans	1	-	-	1
H. influenzae type b	-	-	-	-
DNA of				
N. meningitidis group B	8	-	-	8
N. meningitidis group C	1		1	2
N. meningitidis group Y	2	-	-	2
S. pneumoniae	13	1	1	15
Subtotal	**25** *	**1**	**2**	**28**
Antigen and PCR target negative	**126**	**5**	**3**	**134**
Total	**151**	**6**	**5**	**162**

* From 8 patients with a *S. pneumoniae* isolated from blood, the CSF was culture-negative but PCR-positive for pneumococcal DNA.
From 3 patients with a *N. meningitidis* isolated from blood, the CSF was culture-negative but PCR-positive for meningococcal DNA.

12 VACCINATION PROSPECTS

12.1 N. meningitidis

In the Netherlands, vaccination against serogroup C meningococcal disease has been introduced in June, 2002. All children born on or after June 1st, 2001 are vaccinated at the age of 14 months as part of the regular National Immunisation Programme. In addition, between June, 2002 and October, 2002 children and adolescents from 14 months to 19 years have been vaccinated. In 2013, 6 cases of meningococcal disease (5.4% of all cases, table 4.4) were due to serogroup C meningococci (2012: 2.5%; 2011: 3.3%; 2010: 4.5%; 2009: 6.5%; 2002: 36%). All six patients were not vaccinated because of age (12 months, 44, 77, and 90 years of age) or nationality (Poland). This indicates that the vaccination programme is successful. (figure 12.1)



Figure 12.1 *Age distribution of N.meningitidis serogroup C invasive disease in the first 24 years of life, 1999-2013*

A PorA-based protein vaccine composed of nine different genosubtypes (P1.7,16; P1.5-1,2-2; P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1 and P1.18-1,3,6), if available, would have prevented 72 cases (87%; table 4.9) of serogroup B meningococcal disease and 97 (87%) of all cases of meningococcal disease.

12.2 H. influenzae

The existing *H. influenzae* vaccine consists of the type b polysaccharide conjugated to a protein, tetanus toxoid. Since July 1993, children born after the first of April 1993 are vaccinated with the PRP-T vaccine, at first at the age of 3, 4, 5, and 11 months, and since 1999 at the age of 2, 3, 4 and 11 months. The effect of vaccination on the frequency of *H. influenzae* meningitis cases is shown in figure 12.2. The number of *H. influenzae* meningitis cases gradually decreased since the introduction of the vaccine, while the number of meningitis cases caused by *H. influenzae* non-type b did not alter. In 2013, the number of invasive isolates of *H. influenzae* type b, received from patients that should have been vaccinated (<20 years of age) increased from 11 to 14 in 2013 (2013: 14; 2012: 11; 2011: 7; 2010: 10 and 2009: 10) (figure 12.2 and 12.3). Of those 14 patients, seven had received all doses of the vaccine and seven patients were not vaccinated.



Figure 12.2 *The distribution of H. influenzae type b and non-type b meningitis cases according to annual quarter, 1990 –2013*



Figure 12.3 *The distribution of H. influenzae type b cases (CSF or blood) among patients eligible for vaccination and among older patients, 2004 –2013*

12.3 S. pneumoniae

The pneumococcal conjugated polysaccharide vaccine contains 7 serotype-specific polysaccharides linked to inactive diphtheria toxin (7-valent polysaccharide conjugate vaccine. PCV7). Since July 2006, children born after the first of April 2006 are vaccinated with this vaccine at age of 2, 3, 4 and 11 months. In April 2011 the 10-valent vaccine (PCV10) was introduced for all newborns born since March 1, 2011. In 2013, Five percent of the CSF isolates were of a serotype covered by this hepta-valent conjugate polysaccharide vaccine, while 18% of the isolates were covered by the 10-valent vaccine (table 6.6). The proportion of CSF isolates with a PVC7 serotype from te last year was lower than in previous years (2013: 5%; 2012:11% ; 2011:12%; 2010: 12%; 2009: 18%; 2008: 35%; 2007: 42%; 2006: 56%; 2005: 46%; 2004: 53%; 2003: 52%), most probably as a result of the vaccination. There were 7 patients with an invasive disease due to *S. pneumoniae* with a vaccine (PVC7) serotype (4, 9V, 18C and 19F). One case of serotype 19F invasive pneumococcal disease, was 6 years of age and received all doses of PCV7. The remaining 6 cases were not vaccinated because of age (29, 60, 62, 75 and 76 yr). There were two young children with an invasive disease due to *S. pneumoniae* with a (PVC10) vaccine serotype (7F). Those two children were not vaccinated because of age. The beneficial effect of vaccination is partly abrogated by an increase of the number of cases due to non-vaccine types (figure 12.4).

The pneumococcal non-conjugated polysaccharide vaccine contains 23 serotype-specific polysaccharides. Seventy-one percent of the CSF isolates were of a serotype which is represented in this vaccine (type 6A, which is not included in the vaccine but cross-reacts with 6B, accounted for another 0.7%) (table 6.6) (2012: 77%; 2011: 87%; 2010: 84%; 2009: 85%; 2008: 89%; 2007: 90%).



Figure 12.4 *The age distribution of S.pneumoniae invasive disease due to pneumococci of serotypes included in the hepta-valent conjugated polysaccharide vaccine, 2004-2013. Left: vaccine types. Right: types not included in this vaccine*

13 PUBLICATIONS

1 Adriani KS, Brouwer MC, Geldhoff M, Baas F, Zwinderman AH, Paul Morgan B, Harris CL, van der Ende A, van de Beek D. Common polymorphisms in the complement system and susceptiblity to bacterial meningitis. J Infect. 2013;66:255-62.

2 Adriani KS, Brouwer MC, van der Ende A, van de Beek D. Bacterial meningitis in adults after splenectomy and hyposplenic states. Mayo Clin Proc. 2013;88:571-8.

3 Arenas J, Schipper K, van Ulsen P, van der Ende A, Tommassen J. Domain exchange at the 3' end of the gene encoding the fratricide meningococcal two-partner secretion protein A. BMC Genomics. 2013;14:622.

4 Bambini S, Piet J, Muzzi A, Keijzers W, Comandi S, De Tora L, Pizza M, Rappuoli R, van de Beek D, van der Ende A, Comanducci M. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One. 2013;8:e65043.

5 Bijlsma MW, Brouwer MC, van den Kerkhof H, Knol MJ, van de Beek D, van der Ende A. No evidence of clusters of serogroup C meningococcal disease in the Dutch MSM community. J Infect. 2014;68:296-7.

6 Brouwer MC, Baas F, van der Ende A, van de Beek D. Genetic variation and cerebrospinal fluid levels of mannose binding lectin in pneumococcal meningitis patients. PLoS One. 2013;8:e65151.

7 Brouwer MC, Jim KK, Benschop KS, Wolthers KC, van der Ende A, de Jong MD, van de Beek D. No evidence of viral coinfection in cerebrospinal fluid from patients with community-acquired bacterial meningitis. J Infect Dis. 2013;208:182-4.

8 Brouwer MC, Meijers JC, Baas F, van der Ende A, Pfister HW, Giese A, van de Beek D, Koedel U. Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. Acta Neuropathol. 2014;127:553-64.

9 Bruin JP, Kostrzewa M, van der Ende A, Badoux P, Jansen R, Boers SA, Diederen BM. Identification of *Haemophilus influenzae* and *Haemophilus haemolyticus* by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Eur J Clin Microbiol Infect Dis. 2014;33:279-84.

10 Burghout P, Quintero B, Bos L, Beilharz K, Veening JW, de Jonge MI, van der Linden M, van der Ende A, Hermans PW. A single amino acid substitution in the MurF UDP-MurNAc-pentapeptide synthetase renders *Streptococcus pneumonia* dependent on CO2 and temperature. Mol Microbiol. 2013;89:494-506.

11 de Jonge R, Sanders M, Terwee C, Heymans M, Gemke R, Koomen I, Spanjaard L, van Furth A. Unsuccessful validation of 2004 model for predicting academic or behavioural limitations after childhood bacterial meningitis. Acta Paediatr. 2013;102:e553-9.

12 de Jonge RC, Sanders MS, Terwee CB, Heymans MW, Gemke RJ, Koomen I, Spanjaard L, van Furth AM. Independent validation of an existing model enables prediction of hearing loss after childhood bacterial meningitis. PLoS One. 2013;8(3):e58707.

13 Geldhoff M, Mook-Kanamori BB, Brouwer MC, Troost D, Leemans JC, Flavell RA, van der Ende A, van der Poll T, van de Beek D. Inflammasome activation mediates inflammation and outcome in humans and mice with pneumococcal meningitis. BMC Infect Dis. 2013;13:358.

14 Geldhoff M, Mook-Kanamori BB, Brouwer MC, Valls Seron M, Baas F, van der Ende A, van de Beek D. Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis. Immunogenetics. 2013;65:9-16.

15 Hasbun R, Bijlsma M, Brouwer MC, Khoury N, Hadi CM, van der Ende A, Wootton SH, Salazar L, Hossain MM, Beilke M, van de Beek D. Risk score for identifying adults with CSF pleocytosis and negative CSF Gram stain at low risk for an urgent treatable cause. J Infect. 2013;67:102-10.

16 Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W_{135} and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One. 2013;8:e65036.

17 Huijts SM, Pride MW, Vos JM, Jansen KU, Webber C, Gruber W, Boersma WG, Snijders D, Kluytmans JA, van der Lee I, Kuipers BA, van der Ende A, Bonten MJ. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J. 2013;42:1283-90.

18 Kaaijk P, van der Ende A, Luytjes W. Routine vaccination against MenB: considerations for implementation. Hum Vaccin Immunother. 2014;10:310-6.

19 Koopmans MM, Brouwer MC, Bijlsma MW, Bovenkerk S, Keijzers W, van der Ende A, van de Beek D. *Listeria monocytogenes* sequence type 6 and increased rate of unfavorable outcome in meningitis: epidemiologic cohort study. Clin Infect Dis. 2013;57:247-53.

20 Lucas MJ, Brouwer MC, van der Ende A, van de Beek D. Endocarditis in adults with bacterial meningitis. Circulation. 2013;127:2056-62.

21 Piet JR, Geldhoff M, van Schaik BD, Brouwer MC, Valls Seron M, Jakobs ME, Schipper K, Pannekoek Y, Zwinderman AH, van der Poll T, van Kampen AH, Baas F, van der Ende A, van de Beek D. *Streptococcus pneumoniae* arginine synthesis genes promote growth and virulence in pneumococcal meningitis. J Infect Dis. 2014 1;209:1781-91.

22 Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Hum Vaccin Immunother. 2013;9:1129-38.

23 Sanders MS, de Jonge RC, Terwee CB, Heymans MW, Koomen I, Ouburg S, Spanjaard L, Morré SA, van Furth AM. Addition of host genetic variants in a prediction rule for post meningitis hearing loss in childhood: a model updating study. BMC Infect Dis. 2013;13:340.

24 Surewaard BG, Trzciński K, Jacobino SR, Hansen IS, Vughs MM, Sanders EA, van der Ende A, van Strijp JA, de Haas CJ. Pneumococcal immune evasion: ZmpC inhibits neutrophil influx. Cell Microbiol. 2013;15:1753-65.

25 Trzciński K, Bogaert D, Wyllie A, Chu ML, van der Ende A, Bruin JP, van den Dobbelsteen G, Veenhoven RH, Sanders EA. Superiority of trans-oral over trans-nasal sampling in detecting *Streptococcus pneumoniae* colonization in adults. PLoS One. 2013;8:e60520.

26 van den Bergh MR, Spijkerman J, Swinnen KM, François NA, Pascal TG, Borys D, Schuerman L, Ijzerman EP, Bruin JP, van der Ende A, Veenhoven RH, Sanders EA. Effects of the 10-valent pneumococcal nontypeable *Haemophilus influenzae* protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56:e30-9.

27 van Mens SP, van Deursen AM, Meijvis SC, Vlaminckx BJ, Sanders EA, de Melker HE, Schouls LM, van der Ende A, de Greeff SC, Rijkers GT. Increased incidence of serotype-1 invasive pneumococcal disease in young female adults in The Netherlands. Epidemiol Infect. 2014;142:1996-9.

14 ACKNOWLEDGEMENTS

Many have contributed to the work of the Reference Laboratory and to this report. We would like to thank:

- the National Institute of Public Health and the Environment (RIVM Bilthoven, dr. J.T. van Dissel and dr. Karin Elberse) for ongoing financial support
- Dr. D. Notermans (Laboratory for Infectious Diseases and Perinatal Screening (LIS), RIVM) for typing of *E. coli* and *S. pyogenes*
- Mrs. A. Arends, Mrs. W.C.M Bril - Keijzers, Mrs. M.M. Feller and Mrs. I.G.A. de Beer for their outstanding technical laboratory assistance
- Mrs. I.G.A. de Beer for preparing data from the computer files and layout of this report